Skip to main content

Mirus to Study Gene Silencing for Pfizer

NEW YORK (GenomeWeb News) — Mirus Bio yesterday said it has signed a two-year, “multi-million dollar” deal with Pfizer to target and suppress the expression of certain genes.
 
Under the deal, Mirus said it will study methods for optimizing gene silencing methods in animals.
 
Mirus said the agreement will help it speed development of delivery methods for its RNAi technology.
 
Mirus markets DNA and siRNA transfection and labeling products, and is developing therapeutic products using its Pathway IV delivery platform.  
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.